Status:
COMPLETED
A COMPARATIVE STUDY BETWEEN 1MG AND 3 MG OF GRANISETRON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING IN STRABISMUS OPHTHALMIC SURGERIES DURING GENERAL ANESTHESIA
Lead Sponsor:
Cairo University
Collaborating Sponsors:
Mohamed Yousry Mohamed
Tamer Fayez Safan
Conditions:
1mg Vs 3 mg of Granisetron
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Investigators aim to determine the optimal dose of granisetron in strabismus ophthalmic surgeries under general anesthesia to prevent postoperative nausea and vomiting
Detailed Description
Postoperative nausea and vomiting (PONV) are common and distressing symptoms after surgery under general anesthesia. Despite advances in balanced anesthesia in recent decades, PONV can result in delay...
Eligibility Criteria
Inclusion
- • Adult patients \> 18 years old.
- ASA I and II.
- Patients scheduled for strabismus surgery.
Exclusion
- • ASA class \> II.
- Patients with known hypersensitivity or contraindication to any of the study medications.
- Patients who had chronic nausea and vomiting or experienced retching, vomiting, moderate to severe nausea in the preoperative day.
- Patients who had received an antiemetic drug in the preoperative day.
- Patients with a body mass index ≥36.
- Pregnant or breast feeding female patient.
- Patients with gastrointestinal diseases.
- Patients with a history of motion sickness, diabetes mellitus, and GIT pathology (gastritis, hematemesis, peptic ulcer).
Key Trial Info
Start Date :
January 8 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 18 2021
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT04918862
Start Date
January 8 2021
End Date
May 18 2021
Last Update
June 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ahmed Abdalla Mohamed
Cairo, Egypt, 11451